MX368912B - Beta-caseína a2 y reducción y prevención de síntomas de intolerancia a la lactosa. - Google Patents

Beta-caseína a2 y reducción y prevención de síntomas de intolerancia a la lactosa.

Info

Publication number
MX368912B
MX368912B MX2016000308A MX2016000308A MX368912B MX 368912 B MX368912 B MX 368912B MX 2016000308 A MX2016000308 A MX 2016000308A MX 2016000308 A MX2016000308 A MX 2016000308A MX 368912 B MX368912 B MX 368912B
Authority
MX
Mexico
Prior art keywords
casein
beta
reducing
lactose intolerance
preventing symptoms
Prior art date
Application number
MX2016000308A
Other languages
English (en)
Other versions
MX2016000308A (es
Inventor
John Clarke Andrew
Suchin Trivedi Malav
Original Assignee
A2 Milk Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52280344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX368912(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A2 Milk Co Ltd filed Critical A2 Milk Co Ltd
Publication of MX2016000308A publication Critical patent/MX2016000308A/es
Publication of MX368912B publication Critical patent/MX368912B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/142Amino acids; Derivatives thereof
    • A23K20/147Polymeric derivatives, e.g. peptides or proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/40Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/19Dairy proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20Milk; Whey; Colostrum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Husbandry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Confectionery (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a la prevención y reducción de los síntomas de intolerancia a la lactosa en un animal comprenden que el animal consuma una composición que contenga beta-caseína, o evitar que el animal consuma la composición, en donde la beta caseína comprende al menos 75% en peso de beta-caseína A2. El efecto es tanto agudo (después de la exposición a la composición) como permanente (exposición futura a la lactosa).
MX2016000308A 2013-07-12 2014-07-10 Beta-caseína a2 y reducción y prevención de síntomas de intolerancia a la lactosa. MX368912B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361845480P 2013-07-12 2013-07-12
PCT/NZ2014/000141 WO2015005804A1 (en) 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Publications (2)

Publication Number Publication Date
MX2016000308A MX2016000308A (es) 2016-11-14
MX368912B true MX368912B (es) 2019-10-21

Family

ID=52280344

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016000308A MX368912B (es) 2013-07-12 2014-07-10 Beta-caseína a2 y reducción y prevención de síntomas de intolerancia a la lactosa.
MX2019012446A MX2019012446A (es) 2013-07-12 2016-01-08 Beta-caseina a2 y reduccion y prevencion de sintomas de intolerancia a la lactosa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019012446A MX2019012446A (es) 2013-07-12 2016-01-08 Beta-caseina a2 y reduccion y prevencion de sintomas de intolerancia a la lactosa.

Country Status (21)

Country Link
US (3) US20160136238A1 (es)
EP (2) EP3542805A1 (es)
JP (2) JP6436592B2 (es)
KR (2) KR102367941B1 (es)
CN (3) CN105431156A (es)
AU (2) AU2014287862B2 (es)
BR (1) BR112016000612B8 (es)
CA (2) CA3214545A1 (es)
CL (1) CL2016000064A1 (es)
DK (1) DK3019180T3 (es)
ES (1) ES2743194T3 (es)
HK (1) HK1223846A1 (es)
IL (2) IL243366B (es)
MX (2) MX368912B (es)
MY (2) MY172939A (es)
NZ (2) NZ754642A (es)
PH (2) PH12016500032A1 (es)
RU (1) RU2671562C2 (es)
SG (2) SG11201510707YA (es)
WO (1) WO2015005804A1 (es)
ZA (1) ZA201600007B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702580B2 (en) * 2015-05-22 2020-07-07 The A2 Milk Company Limited Beta-casein A2 and antioxidant capacity
WO2017003300A1 (en) * 2015-06-29 2017-01-05 The A2 Milk Company Limited A2 beta-casein and viscosity of milk products
EP3436038B1 (en) * 2016-03-30 2021-06-23 The A2 Milk Company Limited Beta-caseins and cognitive function
AU2016424981C1 (en) * 2016-09-30 2024-10-10 The A2 Milk Company Limited Beta-caseins and gut microbiota
NL2019906B1 (en) * 2017-11-14 2019-05-20 Ausnutria Hyproca B V Composition comprising a2 b-casein and a vegetable fat mixture
WO2021003741A1 (zh) * 2019-07-11 2021-01-14 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
CN112205476A (zh) * 2019-07-11 2021-01-12 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451368B1 (en) 1994-04-11 2002-09-17 New Zealand Dairy Board Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
US7094949B2 (en) * 1995-05-16 2006-08-22 A2 Corporation Limited Breeding and milking cows for milk free of β-casein A1
DK0871366T3 (da) 1995-05-16 2005-10-10 A2 Corp Ltd Födevareprodukt og fremgangsmåde til fremstilling heraf
US7029702B2 (en) * 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
CN1159984C (zh) * 1999-06-29 2004-08-04 新西兰奶制品研究所有限公司 基于奶的预防性饮食添加剂
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
US20060280802A1 (en) * 2002-10-04 2006-12-14 Campbell Julie H Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2
RU2370279C2 (ru) * 2003-09-23 2009-10-20 ДСМ Ай Пи ЭССЕТС Б.В. Применение пролинспецифичных эндопротеаз для гидролиза пептидов и белков
CN1899054A (zh) * 2006-07-17 2007-01-24 颜贻谦 去糖牛奶的制作方法
CN102387715A (zh) * 2009-04-03 2012-03-21 雀巢产品技术援助有限公司 奶样饮料
IE86315B1 (en) * 2009-04-15 2013-12-04 Bopa Ireland Ltd A milk product and a process for the preparation thereof
DE102010009582A1 (de) * 2010-02-05 2011-08-11 Vitacare GmbH & Co. KG, 60318 Mittel zur Anwendung bei Lactasemangel und Lactoseintoleranz
CN103315063A (zh) * 2012-03-19 2013-09-25 基斯有限公司 可预防疾病的婴儿配方奶粉
US20170086481A1 (en) * 2014-06-03 2017-03-30 Abbott Laboratories Nutritional compositions comprising a lipophilic active ingredient

Also Published As

Publication number Publication date
IL243366B (en) 2018-11-29
CA2917492A1 (en) 2015-01-15
MY190309A (en) 2022-04-13
SG11201510707YA (en) 2016-01-28
RU2671562C2 (ru) 2018-11-02
WO2015005804A1 (en) 2015-01-15
CA2917492C (en) 2023-11-14
MX2016000308A (es) 2016-11-14
EP3019180A1 (en) 2016-05-18
HK1223846A1 (zh) 2017-08-11
ZA201600007B (en) 2017-11-29
SG10201710237PA (en) 2018-01-30
BR112016000612B1 (pt) 2021-11-03
PH12019550112A1 (en) 2020-09-14
PH12016500032B1 (en) 2016-03-28
IL261143A (en) 2018-10-31
RU2018131604A (ru) 2018-11-20
US20220175882A1 (en) 2022-06-09
AU2014287862A1 (en) 2016-02-11
CN105431156A (zh) 2016-03-23
BR112016000612B8 (pt) 2022-02-22
RU2015156804A (ru) 2017-08-17
EP3019180B1 (en) 2019-05-29
MY172939A (en) 2019-12-16
NZ754642A (en) 2022-09-30
DK3019180T3 (da) 2019-08-26
KR102291660B1 (ko) 2021-08-19
RU2018131604A3 (es) 2022-04-19
MX2019012446A (es) 2020-02-03
PH12016500032A1 (en) 2016-03-28
EP3019180A4 (en) 2017-03-08
RU2015156804A3 (es) 2018-05-31
JP2016523958A (ja) 2016-08-12
IL261143B (en) 2021-02-28
CA3214545A1 (en) 2015-01-15
CN110800803A (zh) 2020-02-18
US20200147173A1 (en) 2020-05-14
JP2018203753A (ja) 2018-12-27
AU2019203684B2 (en) 2021-08-05
KR20200085375A (ko) 2020-07-14
JP6990154B2 (ja) 2022-01-12
JP6436592B2 (ja) 2018-12-12
ES2743194T3 (es) 2020-02-18
CN114832092A (zh) 2022-08-02
KR20160030974A (ko) 2016-03-21
EP3542805A1 (en) 2019-09-25
US20160136238A1 (en) 2016-05-19
AU2014287862B2 (en) 2019-07-11
NZ715985A (en) 2022-09-30
CL2016000064A1 (es) 2016-12-16
KR102367941B1 (ko) 2022-02-24
BR112016000612A2 (es) 2017-07-25
AU2019203684A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
PH12019550112A1 (en) Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
PH12019550096A1 (en) Beta-casein a2 and prevention of inflammation of the bowel
MX2016004927A (es) Composiciones utiles para tratar trastornos relacionados con kit.
MX2020006720A (es) Beta-caseina a2 y niveles de glucosa en sangre.
SG10201808055QA (en) Compositions and methods for reducing major adverse cardiovascular events
MX2015011837A (es) Co-cristale de pirimetanil y tetracarboximida de ditiina seleccionada.
MY182845A (en) Dual-bearing reel
PH12017500763A1 (en) Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
WO2015027160A3 (en) Allosteric modulators of the cannibinoid 1 receptor
IN2014DN06617A (es)
TWD160461S (zh) 電磁閥之部分
IN2013CH04898A (es)
PL406123A1 (pl) Portal internetowy: Twarzą w Twarz
IN2013CH04980A (es)
TWD176685S (zh) 氣體控制裝置之部分
TH159417A (th) องค์ประกอบที่สามารถเซตตัวได้ที่ประกอบรวมด้วยวอลลาสโตไนต์ และ พิวไมซ์ และวิธีการของการใช้งาน
Arif Cluster-based industrial development: the case of the electrical fittings cluster in Sargodha, Pakistan
UA88327U (ru) Способ лечения генерализованного пародонтита при сахарном диабете типа 2
EA201991189A1 (ru) СТИМУЛЯТОРЫ sGC
TR201010571U (tr) Sunum ve bakım kiti.
TR201900511T4 (tr) Metalik ditiyokarbamatların preparasyonuna yönelik yöntem.
PL405631A1 (pl) Zasilacz dynamiczny
UA85296U (en) Dietetic supplement "hawthorn elixir"
PL122597U1 (pl) Łącznik flagi
UA56040U (en) 1,3-dimethyl-7-n-chlorobenzene-8-n-bromobenzylidene hydrazinoxanthine exhibiting diuretic and anti-oxidant action

Legal Events

Date Code Title Description
FG Grant or registration